PATIENT RESOURCES

• Do not have SHINGRIX if you are allergic (hypersensitive) to any of the ingredients contained in SHINGRIX.
• The most common side effects are headache; stomach and digestive complaints (including nausea, vomiting, diarrhoea and/or stomach pain); muscle pain (myalgia); pain, redness and swelling at the injection site; and tiredness, chills, fever. Most side effects have a duration of 1–3 days.^3,5
• As with all vaccines, SHINGRIX may not fully protect all people who are vaccinated.

SHINGRIX (Recombinant Varicella Zoster Virus Glycoprotein E antigen 50 micrograms (AS01B adjuvanted vaccine)) is indicated for the prevention of herpes zoster (HZ) and post-herpetic neuralgia in adults 50 years of age or older and for adults 18 years of age or older who are at increased risk of herpes zoster. SHINGRIX is a prescription medicine and is fully funded for individuals aged 65 years only. Costs will apply for people who are not 65 years old. A single 0.5 mL dose contains 50 micrograms of gE antigen, adjuvanted with AS01B (composed of the plant extract Quillaja saponaria saponin (QS-21) (50 mcg) and 3-O-desacyl-4’-monophosphoryl lipid A (MPL) from Salmonella minnesota (50 mcg) plus excipients). SHINGRIX should not be administered if you are hypersensitive to any component of this vaccine. SHINGRIX has risks and benefits – ask your doctor if SHINGRIX is right for you. Use strictly as directed. Common side effects: Adults ≥50 years: pain, redness and swelling at the injection site, muscle pain, fatigue, headache, shivering, fever, and gastrointestinal symptoms. This is not a full list. Vaccination with SHINGRIX may not protect all vaccine recipients. If you have side effects, see your doctor, pharmacist or healthcare professional. Additional product information and Consumer Medicine Information (CMI) is available at www.medsafe.govt.nz. Trademarks are owned by or licensed to the GSK group of companies. ©2023 GSK group of companies or its licensor. Marketed by GlaxoSmithKline NZ Ltd, Auckland. Adverse events involving GlaxoSmithKline products should be reported to GSK Medical Information on 0800 808 500. TAPS DA2243ND-PM-NZ-SGX-WCNT-210004. Date of Approval: 02 2023. Date of Expiry: 02 2025.